Shares of Spark Therapeutics Inc (NASDAQ:ONCE) were down 7.6% during trading on Monday . The stock traded as low as $61.23 and last traded at $62.41. Approximately 816,929 shares changed hands during mid-day trading, an increase of 6% from the average daily volume of 769,435 shares. The stock had previously closed at $67.51.
Several analysts have commented on ONCE shares. SunTrust Banks raised their price objective on Spark Therapeutics to $113.00 and gave the company a “buy” rating in a report on Thursday, January 4th. ValuEngine lowered Spark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Credit Suisse Group started coverage on Spark Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price objective on the stock. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. Finally, Barclays reissued a “buy” rating and issued a $64.00 price objective (up from $61.00) on shares of Spark Therapeutics in a report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $70.58.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.73). The firm had revenue of $7.41 million for the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. equities analysts expect that Spark Therapeutics Inc will post -3.42 EPS for the current fiscal year.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.